Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Glioblastoma
75%
Tumor
48%
High-grade Glioma
47%
Newly Diagnosed Glioblastoma
37%
Bevacizumab
37%
Temozolomide
34%
Radiation Therapy
34%
Brain Tumor
32%
Glioblastoma multiforme
25%
Radiotherapy
25%
Primary Brain Tumor
24%
Glioma
23%
Overall Survival
22%
Isocitrate Dehydrogenase 1 (IDH1)
20%
NRG Oncology
19%
Tumor Treating Fields
19%
Dynamic Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI)
18%
Radiation Therapy Oncology Group
17%
Progression-free Survival
16%
Dynamic Contrast-enhanced
14%
Recurrent Glioblastoma
14%
Cardiac Magnetic Resonance Imaging (cMRI)
14%
Glioma Patients
13%
Hazard Ratio
13%
Chemotherapy
13%
Phase I Study
12%
Recursive Partitioning Analysis
12%
Low-grade Glioma
12%
Surgical Resection
12%
Median Overall Survival
11%
Southwest Oncology Group
11%
Vorasidenib
11%
Brain Metastases
11%
Immune Checkpoint Inhibitors
10%
Newly Diagnosed
10%
Vasogenic Edema
10%
Oncology
9%
Neuro-oncology
9%
Tumor Progression
9%
Anaplastic Astrocytoma
9%
Cisplatin
9%
Immune Checkpoint Therapy
8%
Malignant Glioma
8%
Failed Repair
8%
Patient Survival
8%
95% Confidence Interval
8%
Chemoradiation
8%
Partial Response
8%
Patient Outcomes
8%
Methylation Status
8%
Medicine and Dentistry
Glioblastoma
100%
Ganglioglioma
63%
Radiation Therapy
54%
Neoplasm
41%
Oncology
34%
Chemotherapy
32%
Temozolomide
32%
Intracranial Tumor
24%
Overall Survival
24%
Magnetic Resonance Imaging
20%
Bevacizumab
19%
Progression Free Survival
17%
Tumor Treating Fields
15%
Malignant Neoplasm
14%
Tumor
14%
Diseases
13%
Clinical Trial
12%
Meningioma
11%
Vorasidenib
11%
Methylation
10%
Central Nervous System Tumor
10%
Edema
9%
Chemoradiotherapy
9%
Neurologic Disease
9%
Tumor Progression
9%
Neuro-Oncology
9%
Cisplatin
9%
External Beam Radiotherapy
9%
Immunotherapy
9%
Oligoastrocytoma
8%
Isocitrate Dehydrogenase
8%
Oligodendroglioma
8%
Hazard Ratio
8%
Arm
8%
Group Trial
8%
Recursive Partitioning
7%
Treatment Response
7%
Recurrent Disease
7%
DNA Mismatch Repair
7%
Medulloblastoma
7%
Encephalitis
7%
Carmustine
7%
Brain Metastasis
7%
Placebo
6%
Karnofsky Performance Status
6%
T Cell
6%
Monotherapy
6%
Drug Megadose
6%
Survival Rate
5%
Re-Irradiation
5%